[Regression of left ventricular mass in arterial hypertension. Efficacy of 3 different treatment protocols]

J R González-Juanatey1, A Amaro Cendón, C Calvo Gómez

  • 1Unidad Coronaria, Hospital Xeral de Galicia, Facultad de Medicina, Santiago de Compostela, La Coruña.

Medicina Clinica
|March 21, 1992
PubMed

Insights

Atenolol and enalapril demonstrated superior antihypertensive efficacy during exercise compared to chlorthalidone. Both atenolol and enalapril effectively reduced left ventricular mass in hypertensive patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Hypertension poses a significant risk factor for cardiovascular disease.
  • Left ventricular mass is a key indicator of cardiac remodeling in hypertensive individuals.

Purpose of the Study:

  • To compare the antihypertensive efficacy of chlorthalidone, atenolol, and enalapril at rest and during exercise.
  • To assess the impact of these antihypertensive drugs on left ventricular mass.

Main Methods:

  • A study involving 50 hypertensive males (mean age 51 years) treated with chlorthalidone (n=15), atenolol (n=20), or enalapril (n=15).
  • Blood pressure and echocardiograms were recorded at baseline and at 3, 6, and 9 months.
  • Interventricular septum thickness, posterior left ventricular wall thickness, and left ventricular mass index were measured.

Main Results:

  • All three drugs showed similar antihypertensive efficacy at rest.
  • Atenolol and enalapril exhibited superior efficacy during exercise compared to chlorthalidone.
  • Significant reductions in interventricular septum thickness, posterior left ventricular wall, and left ventricular mass index were observed with atenolol and enalapril.

Conclusions:

  • Atenolol and enalapril are more effective than chlorthalidone in managing exercise-induced hypertension.
  • Atenolol and enalapril effectively induce regression of left ventricular mass, suggesting a cardioprotective effect.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...